Michael A. Esposito, R. Ph.; MBA

Mr. Esposito is President and Partner at Norbridge Consulting, Inc. and based in our Massachusetts Mattapoisett office.  He has been a strategic consultant to health care products companies in pharmaceuticals, biotechnology, diagnostics and medical devices for nearly 40 years. 

 

Professional Experience

Norbridge Inc.

1998 – Present President and Partner

 

Arthur D. Little, Inc.

1983 – 1998 Vice President, Director and Global Practice Leader Health Industries

 

Pfizer, Inc

1981 - 1983

Product Management: MARAX®; SUSTAIRE® and SINEQUAN®; Westchester County Sales Territory

 

Mr. Esposito has been involved in a variety of functional and corporate planning assignments and representative consulting assignments include:

Strategic Planning

An evaluation, for many companies, of the requirements for success within the pharmaceutical and medical equipment/supplies/device industries:

  • For a leading medical supplies company, he developed a long-term strategy for continued superior performance in the US market.

  • For a European pharmaceutical company, he developed a strategic plan for expansion.  It became one of the top 10 global pharmaceutical firms.

  • For a major diversified company, he developed the company valuation and the exit strategy from a health care business.

  • For a leading biotechnology company, Mr. Esposito led a team evaluating corporate development options, including acquisition analysis of two companies and one major product.

  • For the past twelve years, he has worked with a mid-size specialty pharmaceutical company on its strategic plan, including product line strategy, new product development, global expansion and financial forecasting.

 

Corporate Development

  • For a major US pharmaceutical firm, he co-managed the sale of a product line including valuation; development of the offering memorandum; marketing strategy; candidate contact; bid solicitation, evaluation and negotiation; and, management of due diligence.

  • For a leading pharmaceutical company and a small start-up firm, he facilitated the development of US strategic alliances.

  • For a leading medical device company, he led a team through the due diligence process during an acquisition in the field of Less Invasive Surgery.

  • L&A/M&A assessments; portfolio valuations and transaction support for numerous clients

 

R&D

  • As part of a company’s downsizing and rationalization process, Mr. Esposito evaluated the effectiveness of the firm’s R&D function.  Specific recommendations for a restructuring process, organizational redesign and resource allocation were implemented.

  • For several leading pharmaceutical, medical device and diagnostic companies, he has directed strategic assessments of their R&D direction and portfolios, including valuation and prioritization.

 Operations

  • For a leading diversified health care company, Mr. Esposito examined channel strategy and supply chain issues.

  • For several different pharmaceutical firms, Mr. Esposito led plant and distribution rationalization programs.

Marketing & Sales/Commercial Brand and Launch Strategy

  • Mr. Esposito has worked with leading domestic and international firms to evaluate the effectiveness of its marketing, sales and distribution function in the US.  This has included sales force sizing, deployment, function, competence and compensation.

  • For a variety of pharmaceutical, medical product and diagnostic companies, Mr. Esposito has prepared business and strategic plans for new businesses and/or products.  Illustrative categories include CV, CNS, Oncology, Urology, GI, Anti-Infectives & HIV, Diabetes and Pain therapeutic areas; orthopedic implants; in vivo and in vitro diagnostics; Diagnostic Imaging, and, Wound Care.  These plans have included new and in-line products.

  • For Pharmaceutical, Medical Device and Diagnostics firms, Mr. Esposito has led or participated in organizational and sales effectiveness projects, including deployment, sales effectiveness, sales targeting, selling process, compensation and skills development.

CRM/IT

  • For a biotechnology company, Mr. Esposito led a Physician Practice Management initiative that included sales force management and training.  Norbridge developed PC-based tools to be used by physicians, practice staff and sales representatives. 

  • For a leading pharmaceutical firm, Mr. Esposito led an effort to design its business reporting requirements for management, marketing and sales, participate in software and implementation partner selection and organization adoption.

Education

1981 MBA from the Amos Tuck School at Dartmouth College (1981)

1978 BS in Pharmacy from the Massachusetts College of Pharmacy (now MCPHS University)

Registered Pharmacist: Commonwealth of Massachusetts 1981 to 2022

 

Board Memberships

Mr. Esposito was a member of the Board of Directors at Angioblast Systems, Inc. (Private; 2002 to 2010 and acquired by Mesoblast, Inc. in 2010) and at Aspect Medical Systems, Inc. (NASDAQ: ASPM 2006-2009; acquired by Covidien in 2009). In 2016, he joined the board of Saladax, Inc., a private diagnostics company in Therapeutic Drug Monitoring (TDM).  He is a former Trustee and Chairman of the Annual Appeal for the Rotch-Jones-Duff House & Garden Museum.  He is a member of the Board of Trustees of the New Bedford Symphony Orchestra, and a member of the Corporation of MCPHS University (formerly The Massachusetts College of Pharmacy and Health Sciences).